E-LIB Suche - Ergebnisse für: F Smit, Egbert

1

INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib i..:

F Smit, Egbert ; Dooms, Christophe ; Raskin, Jo...
Future Oncology. 18 (2021) 9 - p. 1039-1054 , 2021

Link: https://doi.org/10.2217/..

2

BRAFV600E-mutant metastatic NSCLC: disease overview and tre..:

Planchard, David ; Sanborn, Rachel E. ; Negrao, Marcelo V...
npj Precision Oncology. 8 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

3

Recommendations for reporting tissue and circulating tumour..:

Malapelle, Umberto ; Leighl, Natasha ; Addeo, Alfredo...
British Journal of Cancer. 131 (2024) 2 - p. 212-219 , 2024

Link: https://doi.org/10.1038/..

4

Author Correction: BRAFV600E-mutant metastatic NSCLC: disea..:

Planchard, David ; Sanborn, Rachel E. ; Negrao, Marcelo V...
npj Precision Oncology. 8 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

5

Integrated non-invasive diagnostics for prediction of survi..:

Yeghaian, Melda ; Bodalal, Zuhir ; Tareco Bucho, Teresa M....
Immuno-Oncology and Technology. , 2024

Link: https://doi.org/10.1016/..

6

A plain language summary of the PHAROS study: the combinati..:

Riely, Gregory J ; Smit, Egbert F ; Ahn, Myung-Ju...
Future Oncology. 20 (2024) 16 - p. 1047-1055 , 2024

Link: https://doi.org/10.2217/..

7

Trastuzumab deruxtecan in HER2-mutant non-small-cell lung c..:

Smit, Egbert F.
Future Oncology. , 2024

Link: https://doi.org/10.1080/..

8

Blood platelet RNA profiles do not enable for nivolumab res..:

Muller, Mirte ; Best, Myron G. ; van der Noort, Vincent...
Tumor Biology. 46 (2024) s1 - p. S327-S340 , 2024

Link: https://doi.org/10.3233/..

9

Combining Genomic Biomarkers to Guide Immunotherapy in Non–..:

van de Haar, Joris ; Mankor, Joanne M. ; Hummelink, Karlijn...
Clinical Cancer Research. 30 (2024) 7 - p. 1307-1318 , 2024

Link: https://doi.org/10.1158/..

10

Treatment decision for recurrences in non-small cell lung c..:

Mirza, Myriam ; Shrivastava, Aseem ; Matthews, Cecile...
Frontiers in Oncology. 13 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

11

Trastuzumab deruxtecan in patients with metastatic non-smal..:

Smit, Egbert F ; Felip, Enriqueta ; Uprety, Dipesh...
The Lancet Oncology. 25 (2024) 4 - p. 439-454 , 2024

Link: https://doi.org/10.1016/..

12

Can blood-based markers predict RECIST progression in non-s..:

Yeghaian, Melda ; Tareco Bucho, Teresa M. ; de Bruin, Melissa...
Journal of Cancer Research and Clinical Oncology. 150 (2024) 6 - p. , 2024

Link: https://doi.org/10.1007/..

13

Cemiplimab in locally advanced or metastatic cutaneous squa..:

Verkerk, Karlijn ; Geurts, Birgit S. ; Zeverijn, Laurien J....
The Lancet Regional Health - Europe. 39 (2024) - p. 100875 , 2024

Link: https://doi.org/10.1016/..

14

The role of anti-EGFR therapies in EGFR-TKI-resistant advan..:

Ciardiello, Fortunato ; Hirsch, Fred R. ; Pirker, Robert...
Cancer Treatment Reviews. 122 (2024) - p. 102664 , 2024

Link: https://doi.org/10.1016/..

15

Model-Informed Development of a Cost-Saving Dosing Regimen ..:

Moes, Dirk J. A. R. ; Hendrikx, Jeroen J. M. A. ; Guchelaar, Henk-Jan...
Targeted Oncology. , 2024

Link: https://doi.org/10.1007/..